• Acumen Pharmaceuticals director Porter Derrell sold 32,300 common shares on June 15-16 at about $2.33 per share.
• Sales followed option exercises totaling 19,500 shares at $1.07 on June 15 and June 17.
• Derrell ended June 17 with 35,500 common shares beneficially owned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-043987), on June 17, 2026, and is solely responsible for the information contained therein.